267 related articles for article (PubMed ID: 8944370)
1. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
Karamanolis DG; Papatheodoridis GV; Xourgias V
Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
[TBL] [Abstract][Full Text] [Related]
2. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
3. Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Ewe K; Becker K; Ueberschaer B
Z Gastroenterol; 1996 Apr; 34(4):225-9. PubMed ID: 8686349
[TBL] [Abstract][Full Text] [Related]
4. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Staerk Laursen L; Stokholm M; Bukhave K; Rask-Madsen J; Lauritsen K
Gut; 1990 Nov; 31(11):1271-6. PubMed ID: 2253912
[TBL] [Abstract][Full Text] [Related]
5. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation.
Gionchetti P; Campieri M; Venturi A; Rizzello F; Ferretti M; Brignola C; Miglioli M
Aliment Pharmacol Ther; 1996 Aug; 10(4):601-5. PubMed ID: 8853765
[TBL] [Abstract][Full Text] [Related]
6. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
[TBL] [Abstract][Full Text] [Related]
7. Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.
Mahmud N; Weir DG; Kelleher D
Ir J Med Sci; 1999; 168(4):228-32. PubMed ID: 10624358
[TBL] [Abstract][Full Text] [Related]
8. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
[TBL] [Abstract][Full Text] [Related]
9. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
Courtney MG; Nunes DP; Bergin CF; O'Driscoll M; Trimble V; Keeling PW; Weir DG
Lancet; 1992 May; 339(8804):1279-81. PubMed ID: 1349676
[TBL] [Abstract][Full Text] [Related]
10. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
11. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
Tzivras M; Konstandinidis A; Hatzis G; Paraskeva K; Skandalis N; Archimandritis A
Eur J Gastroenterol Hepatol; 1997 Jul; 9(7):729-30. PubMed ID: 9262986
[No Abstract] [Full Text] [Related]
12. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
13. A mesalazine enema for ulcerative colitis.
Drug Ther Bull; 1994 May; 32(5):38-9. PubMed ID: 7635028
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis--results of a field study.
Singer MV; Schmausser H; Schönfeld G
Hepatogastroenterology; 2006; 53(69):317-21. PubMed ID: 16795963
[TBL] [Abstract][Full Text] [Related]
15. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
Birketvedt GS; Berg KJ; Fausa O; Florholmen J
Inflamm Bowel Dis; 2000 Nov; 6(4):275-9. PubMed ID: 11149559
[TBL] [Abstract][Full Text] [Related]
16. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis.
Mahmud N; O'Toole D; O'Hare N; Freyne PJ; Weir DG; Kelleher D
Aliment Pharmacol Ther; 2002 Feb; 16(2):207-15. PubMed ID: 11860403
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
[TBL] [Abstract][Full Text] [Related]
19. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
20. [Mesalazine old and new].
Mañosa M; Domènech E
Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():25-9. PubMed ID: 25443223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
